The Enroute+ Study: Micrometastases and Colon Cancer Prognosis
Author Information
Author(s): Daniel J. Lips, Boukje Koebrugge, Gerrit Jan Liefers, Johannes C. van der Linden, Vincent T.H.B.M. Smit, Hans F.M. Pruijt, Hein Putter, Cornelis J.H. van de Velde, Koop Bosscha
Primary Institution: Jeroen Bosch Hospital and Leiden University Medical Center
Hypothesis
Can adjuvant chemotherapy improve disease-free survival in stage I-II colon cancer patients with micrometastases?
Conclusion
Adjuvant chemotherapy may reduce disease recurrence in high-risk stage I-II colon cancer patients with micrometastases.
Supporting Evidence
- 30% of pN0 colon cancer patients may develop disease recurrence.
- Adjuvant chemotherapy is currently only offered to high-risk stage II colon cancer patients in the Netherlands.
- Micrometastatic disease has been linked to worsened disease-free survival.
Takeaway
Some colon cancer patients have tiny cancer cells that are hard to find. This study is trying to see if giving them extra medicine after surgery can help them stay healthy longer.
Methodology
This is a multicenter, randomized controlled trial involving patients with stage I-II colon cancer who are tested for micrometastases and randomized to receive either chemotherapy or observation.
Potential Biases
Potential biases may arise from the randomization process and patient selection criteria.
Limitations
The study may not be generalizable to all colon cancer patients, as it focuses on a specific subset with micrometastases.
Participant Demographics
Adult patients (age above 18) with stage I-II colon cancer.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website